Current treatment of advanced prostate cancer is hormonal manipulation . But the effect of this treatment usually lasts from 24 to 36 months, at which time patients are refractory to hormonal therapy and may be candidates for chemotherapy Taxotere Taxotere.
The FDA approval is based on the final results of a pivotal phase III trial, which achieved its primary endpoint of survival based fulfilled in this patient group. The critical study TAX 327, along with another study of Taxotere in this patient group for presentation for presentation to the plenary meeting of the American Society of Clinical Oncology Annual Meeting on Monday Elected in June, in New Orleans., A marketing authorization application for Taxotere in prostate cancer is also pending with the European Agency for the Evaluation of Medicinal Products .Artis zee Details at the families from interventional imaging systems will the representatives on the exhibition stand. When there was installed using the unique imaging apply, syngo DynaCT Cardiac, these systems able to delivering 3D and 4D images of the beating heart direct to the cath lab. This improves the decision-making, sequence planning and catheter guidance.